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Methods: A possible disease-modifying effect of solanezumab was assessed using a new statistical
method including noninferiority testing. Performance differences were compared during the placebo-
controlled period with performance differences after the placebo patients crossed over to solanezu-
mab in the delayed-start period.
Results: Noninferiority of the 14-item Alzheimer’s Disease Assessment Scale-Cognitive subscale
(ADAS-Cog14) and Alzheimer’s Disease Cooperative Study Activities of Daily Living inventory
instrumental items (ADCS-iADL) differences was met through 132 weeks, indicating that treatment
differences observed in the placebo-controlled period remained, within a predefined margin, after the
placebo group initiated solanezumab. Solanezumab was well tolerated, and no new safety concerns
were identified.
Discussion: The results of this secondary analysis show that the mild subgroup of solanezumab-
treated patients who initiated treatment early, at the start of the placebo-controlled period, retained
an advantage at most time points in the delayed-start period.
 2015 Eli Lilly and Company. Published by Elsevier Inc. on behalf of the Alzheimer’s Association.
This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Keywords: Solanezumab; Delayed-start; Clinical trials; Alzheimer’s disease; Anti-amyloid-b antibody.H., S.W.A., C.C., G.S., and S.H. are full-time em-
areholders of Eli Lilly and Company. E.S. is chair
ssociation Research Roundtable and has reviewed
er’s Association. I.L. is a former full-time employee
pany and a current full-time employee of Quintiles.
ployee of Quintiles. R.S.D. has consulted for AC Im-
Biogen, Biotie, Cerespir, Forum, Genentech, Glax-
an LaRoche, Merck, Nutricia, Shanghai Green
ces, Suven, Transition, and Takeda about AD drug
rimental agents and received one honorarium from
in a CME program; she has served as PI for clinical
ir, Genentech, Lilly/NIA, Merck, NIH, Pfizer, and
institution receives payment and has stock options
in AZ Therapies, QR Pharma, Sonexa, and Transition. P.A. has served
as a consultant to the following companies: NeuroPhage, Elan, Eisai,
Bristol-Myers Squibb, Eli Lilly, Merck, Roche, Amgen, Genentech, Ab-
bott, Pfizer, Novartis, AstraZeneca, Janssen, Medivation, Ichor, Toyama,
Lundbeck, Biogen Idec, iPerian, Probiodrug, Somaxon, Biotie, Cardeus,
Anavex, Abbvie, and Cohbar. P.A. receives research support from Eli Lilly
and Company, NIH (NIA U01-AG10483 [PI], NIA U01-AG024904 [Coor-
dinating Center Director], NIA R01-AG030048 [PI], and R01-AG16381
[Co-I]).
*Corresponding author. Tel.: 11-317-433-0662; Fax: 11-317-276-
5791.
E-mail address: liu-seifert_hong@lilly.com
16/j.trci.2015.06.006
i Lilly and Company. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CCBY-
//creativecommons.org/licenses/by-nc-nd/4.0/).
H. Liu-Seifert et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 111-1211121. Introduction
Alzheimer’s disease (AD) is an age-related neurodegen-
erative disorder characterized by a progressive decline in
cognitive function. Currently approved treatments attenuate
the symptoms of AD but have not been shown to affect the
underlying pathology [1]; thus, they are sometimes termed
“symptomatic” treatments. Leber (1997) [2] proposed the
delayed-start design as a method for demonstrating a
disease-modification drug effect; that is, an effect that slows
the progression of disease by modifying the underlying bio-
logical pathology, rather than only attenuating symptoms.
The delayed-start, also known as randomized-start, study
design is one in which patients are randomized to the same
active treatment but starting at different times, resulting in
two treatment periods: a placebo-controlled period followed
by a delayed-start period. During the placebo-controlled
period, patients receive either an active treatment or placebo.
During the delayed-start period, placebo patients are
switched to active treatment and thus become delayed-start
patients. Patients on active treatment during the placebo-
controlled period continue to receive active treatment during
the delayed-start period and are labeled as early-start
patients. Thus, in a delayed-start study, patients are random-
ized at the beginning of the placebo-controlled period to be
either early- or delayed-start patients. During the entire
length of the study (that is, both the placebo-controlled
and delayed-start periods), this randomization to treatment
group is blinded to all patients and study personnel. If the
treatment difference observed at the end of the placebo-
controlled period was preserved at the end of the delayed-
start period (that is, delayed-start patients do not “catch
up” with the early start patients), the treatment effect is
considered consistent with a disease-modifying effect.
There have been very limited published data on delayed-
start studies; one example is the Attenuation of Disease Pro-
gression with Azilect Given Once-daily (ADAGIO) study, a
study of rasagiline conducted to assess possible disease-
modification effects in Parkinson’s disease. However, the
study included some methodological issues and a lack of
dose response made the results difficult to interpret [3]. Other
studies have reported the long-term use of symptomatic drugs
in a framework similar to the delayed-start design, either with
or without placebo wash-out periods [4,5]. Although
these studies suggested that continued treatment with
symptomatic drugs may offer longer term benefit, no
quantitative methods were applied to assess whether the
differences between early-start and delayed-start patients
were due to chance and whether delayed-start patients had
caught up with early-start patients within a statistical margin.
We recently proposed a new method for delayed-start
analyses that includes comparisons of treatment differences
at the beginning and end of the delayed-start period using a
noninferiority test. This method uses a single mixed-model
repeated measure (MMRM) analysis model including all
available data from all randomized patients from the begin-ning of the placebo-controlled period through the end of the
delayed-start period. This new method was developed to
mitigate some issues observed with previously applied
methods [6], and its application to data from the solanezu-
mab EXPEDITION program represents the first effort
of a prespecified statistical delayed-start analysis in an AD
study.
1.1. Solanezumab
Solanezumab is an IgG1 anti-amyloid monoclonal anti-
body that binds to the mid-domain of the amyloid-beta
(Ab) peptide and is thought to increase clearance of soluble
Ab. EXPEDITION and EXPEDITION2 were identical
phase 3, 18-month, placebo-controlled studies investigating
solanezumab treatment in patients with mild-to-moderate
AD. EXPEDITION-EXT is an ongoing open-label extension
study offered to patients who completed EXPEDITION or
EXPEDITION2, in which all patients receive solanezumab;
patients, investigators, and site personnel remain blinded
to the original treatment assignment during the placebo-
controlled period. Analyses from the two individual
placebo-controlled studies did not show a significant benefit
of solanezumab for the original coprimary outcomes: the
11-item Alzheimer’s Disease Assessment Scale-Cognitive
subscale (ADAS-Cog11) and the Alzheimer’s Disease
Cooperative Study Activities of Daily Living inventory
(ADCS-ADL) in the mild-to-moderate AD population. In
EXPEDITION, the treatment benefit for solanezumab at
80 weeks was 0.8 points (P 5 .24) for the ADAS-Cog11
and 0.4 points (P 5 .64) for the ADCS-ADL. In
EXPEDITION2, the treatment benefit for solanezumab at
80 weeks was 1.3 points (P 5 .06) for the ADAS-Cog11
and 1.6 points (P 5 .08) for the ADCS-ADL [7]. However,
a key prespecified secondary analysis of the mild AD popu-
lation in EXPEDITION demonstrated a significant effect of
solanezumab on cognition; based on this result, the statisti-
cal analysis plan for EXPEDITION2 was changed such
that the primary outcome was cognition alone (the 14-item
ADAS-Cog [ADAS-Cog14]) in the mild population. This
single primary outcome did not reach statistical significance
in the smaller mild-only subgroup in EXPEDITION2
(P 5 .06) [7]. When examining the mild subgroup in
the larger pooled population from EXPEDITION and
EXPEDITION2, the treatment benefit for solanezumab
was 2.13 points (P 5 .001) for the ADAS-Cog14 and 1.21
points (P 5 .045) for the instrumental items of the ADCS-
ADL (ADCS-iADL) [8]. Delayed-start analyses of the first
interim data cut for EXPEDITION-EXT (through 20 June
2012, including 240 placebo and 232 solanezumab mild
AD patients who had completed 28 weeks of treatment in
the delayed-start period), showed a persistent benefit on
cognition [6]. That is, the treatment difference in cognition
between solanezumab and placebo observed at the end of
the placebo-controlled studies was preserved at 28 weeks
in the delayed-start period. Safety analyses from the
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gram) suggested that solanezumab is well tolerated [7].
Data have subsequently become available for all
patients who have completed 2 years or discontinued in
EXPEDITION-EXT. Delayed-start and safety analyses
have been performed for the entire 3.5-year period
(18 months in the placebo-controlled period, plus 2 years
in the delayed-start period) in the EXPEDITION studies
for the patients who were defined as mild at the start of the
placebo-controlled period. This population was selected
because a delayed-start analysis presupposes an effect at
the end of the placebo-controlled period, which was not
observed in the moderate population in the EXPEDITION
program. As such, the current solanezumab development
program focuses on mild and preclinical AD populations.2. Methods
2.1. Study design
The designs of EXPEDITION and EXPEDITION2
(ClinicalTrials.gov numbers NCT00905372 and
NCT00904683) have been described previously [7]. Briefly,
both were multinational, randomized, double-blind,
placebo-controlled, phase 3 studies of solanezumab given
intravenously 400 mg every 4 weeks in outpatients with
mild-to-moderate AD. Patients were at least 55 years old
and met criteria for probable AD based on National Institute
of Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria [9]. Patients with Mini-Mental Status Examination
(MMSE) [10] scores of 16–26 were allowed to participate.Fig. 1. Model of delayed-start design and analysis in the solanezumab EXPEDIT
T15 end time point in the placebo-controlled period/beginning time point in the de
(multiple time points are analyzed in the MMRM analysis; the primary time point
that is, 28 weeks after the start of the delayed-start period); D1 5 the true treatme
MMRM, mixed-model repeated measure.Mild AD was defined as screening visit MMSE scores of
20–26; moderate AD was defined as screening visit scores
of 16–19. Randomization to treatment was stratified by
AD severity to ensure a balance of treatment assignment
within both mild and moderate AD patients. Patients were
allowed to continue treatment with stable doses of
standard-of-care AD treatments (for example, acetylcholin-
esterase inhibitors and memantine) throughout the studies.
EXPEDITION-EXT (NCT01127633) is an ongoing
extension study in patients who completed EXPEDITION
or EXPEDITION2. During EXPEDITION-EXT, all patients
receive solanezumab 400 mg every 4 weeks starting at week
1 (which is the same as week 80 in the placebo-controlled
studies); however, both patients and site personnel remain
blinded to patients’ original treatment assignment to solane-
zumab or placebo in the placebo-controlled studies. In
EXPEDITION-EXT, patients who received solanezumab
in the placebo-controlled studies remain on active treatment
(early-start), whereas patients who received placebo in the
placebo-controlled studies are switched to solanezumab
(delayed-start).
Together, these studies represent the placebo-controlled
period (EXPEDITION and EXPEDITION2) and the
delayed-start period (EXPEDITION-EXT) in the delayed-
start analysis of the EXPEDITION program (Fig. 1).
The trial protocols were approved by the ethical review
board at each of the 221 study centers in EXPEDITION
and EXPEDITION2 and the 206 study centers in
EXPEDITION-EXT in 16 countries. These studies were
conducted in accordance with the ethical principles that
have their origin in the Declaration of Helsinki and that
are consistent with good clinical practices and theION program. T0 5 beginning time point in the placebo-controlled period;
layed-start period; T25 postbaseline time point in the delayed-start analysis
for the delayed-start analysis in the EXPEDITION program was 108 weeks,
nt difference at T1; D2 5 the true treatment difference at T2. Abbreviation:
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informed consent form was obtained from each subject.2.2. Statistical methods
All statistical analyses were conducted using SAS version
9.2.
2.2.1. Delayed-start analysis
The primary time point for the delayed-start analyses was
the analysis at 108 weeks (that is, 28 weeks after the start of
EXPEDITION-EXT), among the subgroup of patients with
mild AD at baseline. We evaluated the persistence of the
separation between active- and placebo-treated subjects
during the delayed-start period with a noninferiority test
and by determining the statistical significance of the treat-
ment difference, using pooled data from the EXPEDITION,
EXPEDITION2, and EXPEDITION-EXT studies. In addi-
tion, we conducted the delayed-start analysis for additional
time points after 108 weeks, through 184 weeks in the
mild AD population for a total of up to 3.5 years in the
placebo-controlled and delayed-start periods. The statistical
methodologies for the delayed-start analysis described in
this article are described in detail elsewhere [6]; they were
communicated to Food and Drug Administration (FDA)
and were prespecified in the statistical analysis plan before
database locks.
To test for differences in disease progression between the
delayed-start and early-start groups, the change for each ef-
ficacy measure from the beginning of the placebo-controlled
period through the delayed-start period was analyzed with an
MMRM analysis model as described in the following; the
schematics of the design and analysis are shown in Fig. 1.
Efficacy measures included the ADAS-Cog14, ADCS-
iADL, clinical dementia rating scale–sum of boxes (CDR-
SB), MMSE, the 11-item ADAS-Cog (ADAS-Cog11), and
the basic items of the ADCS-ADL (ADCS-bADL).
The MMRM analysis model included all randomized
patients with mild AD and used data from the beginning of
the placebo-controlled period (T0) through the delayed-
start period (T2). The model included terms for seven fixed
effects: baseline score, pooled investigator, treatment, visit,
treatment-by-visit interaction, concomitant acetylcholines-
terase inhibitor (AChEI) and/or memantine use at baseline
(yes or no), and age at baseline (for all variables, baseline
was the beginning of the placebo-controlled period); subject
was considered a random effect. Visit was considered a cat-
egorical variable with values equal to the visit numbers at
which the scales were assessed.
To determine whether the benefits of early treatment can
be matched by later treatment (that is, whether delayed-start
patients can “catch up” with early-start patients), a noninfer-
iority test was conducted. The null and alternative hypothe-
ses of the noninferiority test are described in the following,
where D1 is the true treatment difference at the end of the
placebo-controlled period, D2 is the true treatment differ-ence at the postbaseline time point in the delayed-start
period, and the noninferiority margin was specified as 50%
of the treatment difference observed at the end of the
placebo-controlled period (D1):
H0: D2  0:5D1
H1: D2.0:5D1
which is equivalent to
H0: D220:5D1  0
H1: D220:5D1.0
The noninferiority test was carried out by constructing a
90% one-sided confidence interval for D2–0.5D1. If the
lower limit of the confidence interval is greater than 0, the
null hypothesis is rejected and the noninferiority criterion
is met, indicating that at least 50% of the treatment differ-
ence observed at the end of the placebo-controlled period
has been preserved at the end of the delayed-start period.
In addition, a superiority analysis was conducted on D2
with two-sidedP value of.05 using the sameMMRMmodel
used for the noninferiority analysis mentioned previously.
2.2.2. Safety assessment
Safety was assessed by summarizing adverse events
(AEs) and electrocardiograms for the delayed-start and
early-start treatment groups across the entire EXPEDITION
program (that is, the placebo-controlled and delayed-start
periods). AEs were coded according to established Med-
DRA version 17.0 terms and summarized by MedDRA sys-
tem organ class and preferred term. AEs of special interest
included infusion-related reactions, suicidal ideation or
behavior, hemorrhagic stroke, cardiac ischemic– and
arrhythmia-related events, and amyloid-related imaging
abnormality-hemorrhage/hemosiderin deposition (ARIA-H)
and ARIA-effusion/edema (ARIA-E); these events were
identified as being of special interest because of potential
class effects (infusion reaction and ARIA), observations
from prior studies (cardiac), and regulatory considerations
(suicidal ideation or behavior). All safety variables were
summarized by descriptive statistics and tests of significance
between early-start and delayed-start treatment groups were
calculated using Fisher exact tests. The baseline for safety
analyses was defined as the last nonmissing visit or measure-
ment before the first infusion during EXPEDITION or
EXPEDITION2.
Changes in ARIA-H during the study were calculated
based on the number of patients with both a baseline and
at least one postbaseline magnetic resonance imaging scan
and an increase in number or increase in size of preexisting
ARIA-H. The magnitude of changes in ARIA-H was quan-
tified by number of categorical increases (categories 0, 1,
2–5, 6–10, and .10). A categorical increase was defined
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ARIA-H in the patient with .10 ARIA-H at baseline was
also considered a categorical increase. ARIA-E cases were
summarized by patient.3. Results
The flow of patients included in the delayed-start efficacy
analyses are shown in Fig. 2. A total of 1322 patients with
mild AD were randomized to be either delayed-start
(n 5 663) or early-start (n 5 659) patients. Discontinuation
rates during the placebo-controlled period were similar for
placebo- and solanezumab-treated patients (21.4% and
23.7%, respectively). Of the 1024 patients who comple-
ted the placebo-controlled period (EXPEDITION and
EXPEDITION2), 975 (95.2%) entered the delayed-start
period (EXPEDITION-EXT) and 58.2% of delayed-startFig. 2. Flow of study participants. Abbreviations: AD, Alzheimer’s disease; lab,
Examination. aDisease severity was based on MMSE score at baseline (mild, MM
study eligibility range (.26) for some randomized subjects, and these individu
mild AD data set.(n 5 286) and 61.0% of early-start (n 5 295) patients
completed 2 years in the delayed-start period.
Demographic and clinical characteristics of the mild AD
population at baseline of the EXPEDITION program are
described in Table 1.3.1. Delayed-start
Treatment differences between early-start and delayed-
start groups at 108 weeks since randomization (D2, that is,
28 weeks in the delayed-start period) for ADAS-Cog14 and
ADCS-iADL were similar to differences at the end of the
placebo-controlled period (D1, that is, 80weeks since random-
ization; Fig. 3 and Table 2). The noninferiority and superiority
criteria were both met, indicating the treatment differences
in cognition and function at the end of the placebo-
controlled period were preserved at 108 weeks within alaboratory measure; ECG, electrocardiogram; MMSE, Mini-Mental Status
SE 20–26; moderate, MMSE 16–19). Baseline MMSE was outside of the
als were not categorized based on disease severity or included in pooled
Table 1
Baseline characteristics, mild AD patients in the Expedition program
Characteristics
Delayed-start Early-start Total
P valuen n 5 663 n n 5 659 n 5 1322
Age, mean (SD), y 663 73 (7.9) 659 73 (8.1) 73 (8.0) .169
Female, n (%) 663 362 (54.6) 659 346 (52.5) 708 (53.6) .473
APOE ε4 carriers, n (%) 614 367 (59.8) 595 329 (55.3) 696 (57.6) .117
MMSE, mean (SD) 660 22.5 (2.76) 656 22.5 (2.79) 22.5 (2.78) .699
AChEI or memantine use, n (%) 663 587 (88.5) 659 574 (87.1) 1161 (87.8) .450
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; AChEI, acetylcholinesterase inhibitor; MMSE, Mini-mental status examination.
NOTE. The number of subjects included in each analysis varies based on the number of subjects with a baseline value for that measure.
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start period, treatment differences for ADAS-Cog14 were
significant through 160 weeks and noninferiority was met
through 132 weeks. For ADCS-iADL, treatment differences
were significant and noninferiority was met through
132 weeks. For ADAS-Cog14, ADCS-iADL, and MMSE,Fig. 3. Delayed-start analysis of ADAS-Cog14, ADCS-iADL, MMSE, and CDR-S
through 3.5 years. P values for treatment difference shown at all time points at w
Assessment Scale-Cognitive subscale; ADCS-iADL, Alzheimer’s Disease Coo
MMSE, Mini-Mental Status Examination; CDR-SB, Clinical Dementia Rating S
met (90% one-sided confidence interval for D2 – 0.5D1 .0); LS, least squares.treatment differences increased steadily during the placebo-
controlled period and remained stable in the delayed-start
period. For the CDR-SB, treatment differences were small
during the placebo-controlled period but increased over the
delayed-start period (Fig. 4). Visual representations of the
noninferiority statistics are presented in Supplementary Fig. 1.B among patients with mild AD in the solanezumab EXPEDITION program
hich P , .05. Abbreviations: ADAS-Cog14, 14-item Alzheimer’s Disease
perative Study Activities of Daily Living inventory, instrumental items;
cale-Sum of Boxes; AD, Alzheimer’s disease; NI, noninferiority criterion
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similar treatment differences over the delayed-start period
with statistical significance at 132 and 160 weeks. Noninfer-
iority was not met at any time point (Fig. 3 and Table 2).
Treatment differences on the CDR-SB increased over the
delayed-start period, and statistical significance was reached
at 184 weeks. Noninferiority was met at 108, 160, and
184 weeks; however, these results are limited in support of
a delayed-start effect because a statistically significant treat-Table 2
Treatment difference and noninferiority from delayed-start analyses of the solane
Scale, time point
Delayed-start Early-start
n LS mean change (SE) n LS mean
ADAS-Cog14, wk
Baseline 660 654
12 632 20.49 (0.441) 613 20.62
28 588 0.73 (0.490) 570 0.63
40 571 0.80 (0.492) 552 20.01
52 551 3.39 (0.498) 539 2.50
64 535 4.03 (0.514) 519 2.79
80 520 6.02 (0.540) 498 4.18
108 441 9.52 (0.577) 441 7.77
132 389 12.06 (0.630) 406 10.14
160 334 14.19 (0.698) 357 12.35
184 303 16.42 (0.796) 323 15.02
ADCS-iADL, wk
Baseline 660 652
12 631 20.79 (0.434) 609 20.70
28 589 21.90 (0.463) 569 21.77
40 572 22.77 (0.471) 547 22.34
52 554 23.98 (0.480) 538 23.16
64 537 25.26 (0.486) 517 24.19
80 521 26.80 (0.504) 500 25.64
108 441 28.73 (0.542) 443 27.47
132 390 211.42 (0.589) 405 29.75
160 336 213.32 (0.628) 358 212.13
184 308 215.33 (0.694) 320 213.95
MMSE, wk
Baseline 660 654
28 591 20.52 (0.232) 572 20.51
52 554 21.67 (0.251) 537 21.36
80 521 22.98 (0.265) 499 22.16
108 439 23.96 (0.278) 440 23.48
132 387 25.01 (0.287) 404 24.36
160 335 26.26 (0.308) 354 25.52
184 303 26.96 (0.329) 319 26.20
CDR-SB, wk
Baseline 660 652
28 587 0.52 (0.104) 569 0.33
52 553 1.15 (0.120) 536 0.96
80 521 1.85 (0.142) 499 1.63
108 440 2.71 (0.166) 436 2.39
132 387 3.43 (0.185) 403 3.11
160 334 4.25 (0.204) 352 3.79
184 305 5.21 (0.232) 320 4.57
Abbreviations: AD, Alzheimer’s disease; LS, least squares; SE, standard error;
period; D1, treatment difference at the end of the placebo-controlled period; ADAS
CI, confidence interval; ADCS-iADL, Alzheimer’s Disease Cooperative Study Ac
Status Examination; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes.
*LS mean difference values are absolute values representing less worsening inment effect was not observed at the end of the placebo-
controlled period for the CDR-SB.
The delayed-start results for ADAS-Cog11 and the
ADCS-bADL are shown in Supplementary Fig. 2. Results
for the ADAS-Cog11 were consistent with the ADAS-
Cog14. Similar to the CDR-SB, the ADCS-bADL did
not achieve statistical significance at the end of the
placebo-controlled period but reached significance in the
delayed-start period.zumab EXPEDITION program through 3.5 y among patients with mild AD
LS mean
difference* P value
Lower limit of 90% CI
for D2–0.5D1 (SE)change (SE)
(0.441) 0.14 .756
(0.491) 0.10 .852
(0.493) 0.81 .128
(0.498) 0.90 .100
(0.515) 1.24 .031
(0.542) 1.83 .003
(0.577) 1.75 .010 0.15 (0.531)
(0.627) 1.91 .013 0.15 (0.657)
(0.689) 1.84 .034 20.09 (0.793)
(0.782) 1.40 .169 20.75 (0.963)
(0.435) 0.09 .823
(0.465) 0.12 .795
(0.473) 0.43 .385
(0.481) 0.72 .158
(0.488) 1.07 .041
(0.507) 1.16 .037
(0.542) 1.26 .043 0.08 (0.463)
(0.587) 1.66 .018 0.35 (0.566)
(0.623) 1.19 .118 20.23 (0.650)
(0.689) 1.38 .111 20.19 (0.776)
(0.230) 0.01 .955
(0.251) 0.31 .217
(0.266) 0.82 .004
(0.278) 0.48 .115 20.20 (0.212)
(0.285) 0.66 .040 20.06 (0.242)
(0.305) 0.75 .036 20.04 (0.291)
(0.327) 0.75 .055 20.10 (0.342)
(0.104) 0.19 .044
(0.119) 0.18 .149
(0.143) 0.22 .189
(0.167) 0.32 .128 0.01 (0.149)
(0.185) 0.32 .170 20.02 (0.181)
(0.203) 0.46 .085 0.08 (0.211)
(0.230) 0.64 .039 0.20 (0.257)
D2, treatment difference at the postbaseline time point in the delayed-start
-Cog14, 14-item Alzheimer’s Disease Assessment Scale-Cognitive subscale;
tivities of Daily Living inventory, instrumental items; MMSE, Mini-Mental
the early-start group relative to the delayed-start group.
Fig. 4. Differences in least squares means between delayed-start and early-start treatment groups and 95% confidence intervals for ADAS-Cog14, ADCS-iADL,
CDR-SB, and MMSE among patients with mild AD in the solanezumab EXPEDITION program through 3.5 years. Shading represents the placebo-controlled
period. Abbreviations: ADAS-Cog14, 14-item Alzheimer’s Disease Assessment Scale-Cognitive subscale; ADCS-iADL, Alzheimer’s Disease Cooperative
Study Activities of Daily Living inventory, instrumental items; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes; MMSE, Mini-Mental Status Exam-
ination; AD, Alzheimer’s disease.
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analyses for EXPEDITION 1 EXPEDITION-EXT and
EXPEDITION2 1 EXPEDITION-EXT) showed similar
patterns in the outcomes between the two studies
(Supplementary Fig. 3).
3.2. Safety
A total of 1322 mild AD patients enrolled in the
EXPEDITION program, representing 3414.4 person-years
of follow-up, with 79.9% of delayed-start and 77.5% of
early-start patients having at least 18 months’ of follow-up.
Deaths, serious AEs, discontinuations due to an AE, and the
incidence of increases in ARIA-H were evenly distributed
across treatment regimen groups (Table 3). In addition, the
severity of changes in ARIA-H (as represented by categorical
increases in number) was evenly distributed across groups
(Supplementary Fig. 4). Eight patients in the delayed-start
group and 11 patients in the early-start group experienced
ARIA-E; however, ARIA-E was not related to symptoms inany patient (see a summary table of the ARIA-E cases in
Supplementary Table 1). Overall, cardiac disorders, as well
as cardiac ischemic-related and cardiac arrhythmia–related
events, were observed in similar proportions across groups
(Table 3). Among the other safety topics of interest (suicidal
ideation or behavior, infusion-related reactions, and hemor-
rhagic stroke), incidence did not differ significantly across
treatment regimen groups (Supplementary Table 2).
Additional AEs are presented in Supplementary Table 2.
4. Discussion
We have proposed a novel statistical methodology for
delayed-start designs to provide evidence supporting a
disease-modifying effect of an investigational treatment
and have applied this methodology to the mild AD subgroup
of patients from the EXPEDITION program. This is the first
delayed-start analysis method that has been implemented
and reported in the field of AD. Using this method, the re-
sults suggest that the possible drug effect demonstrated by
Table 3
Overview of adverse events in mild AD patients, EXPEDITION,
EXPEDITION2, and EXPEDITION-EXT
Events
Delayed-start,
n 5 663, n (%)
Early-start,
n 5 659, n (%)
P
value
Death 24 (3.6) 32 (4.9) .2776
Serious adverse event 239 (36.0) 233 (35.4) .8185
Discontinuation due to
adverse event
106 (16.0) 114 (17.3) .5549
ARIA-H (increase in
number or size)*
82 (12.7) 88 (14.3) .4108
ARIA-E* 8 (1.2) 11 (1.8) .4992
Cardiac disorders SOC 73 (11.0) 92 (14.0) .1140
Cardiac ischemic–related
events
17 (2.6) 25 (3.8) .2134
Myocardial infarction 4 (0.6) 6 (0.9) .5462
Angina pectoris 6 (0.9) 13 (2.0) .1118
Cardiac arrhythmia–related
events
78 (11.8) 94 (14.3) .1911
Prolonged QTcF* 2 (0.3) 4 (0.6) .4434
Abbreviations: AD, Alzheimer’s disease; ARIA-H5 amyloid-related im-
aging abnormality-hemosiderin deposition; ARIA-E 5 amyloid-related
imaging abnormality-edema/effusion; n 5 number of patients enrolled
in EXPEDITION and EXPEDITION2; SOC 5 system organ class;
QTCF 5 QT interval corrected by the Fridericia method.
*Percentages are calculated based on the number of patients with both a
baseline and at least one postbaseline measurement (that is, magnetic reso-
nance imaging [MRI] or electrocardiogram).
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program is consistent with a disease-modifying effect.
There has been very limited literature on delayed-start
studies in neurodegenerative diseases. Previous studies have
reported the long-term use of symptomatic drugs under a
similar delayed-start or a withdrawal framework [4,5]; how-
ever, these studies did not use the same rigorous statistical
methodology that we have used to characterize the
treatment effect. The use of a washout period following a
placebo-controlled period can, in theory, also provide infor-
mation regarding disease modification as in a withdrawal
design [2], although the duration of the washout period
required can be difficult to determine. The Donepezil study
302 used a 6-week placebo washout period, whereas the Do-
nepezil study 301 used a 3-week washout period [4]; the
longer washout period was necessary for patients on active
treatment to decline to the same point as those patients orig-
inally randomized to placebo. Similarly, the Deprenyl and
Tocopherol Antioxidative Therapy of Parkinsonism study
showed that a 1 month and perhaps a 2-month washout period
were not sufficient given the prolonged pharmacodynamic
effects of deprenyl [11]. Thus, complex pharmacokinetic/
pharmacodynamic relationships can add challenges to both
delayed-start and withdrawal study designs.
Until this present study, the ADAGIO study of rasagiline
for the treatment ofParkinson’s diseasewas the onlypublished
study that used the delayed-start design and applied prespeci-
fied statistical analyses to assess whether delayed-start
patients caught up with early-start patients [3]. In 2011, a
US FDA Advisory Committee meeting was held to reviewthe disease-modification claim for rasagiline based on the
ADAGIO study. The committee voted unanimously against
a claim of disease modification for rasagiline, citing, among
other reasons, methodological issues and lack of dose
response [12]. One of the key issues was the use of a noninfer-
iority comparison of slopes at the end of the delayed-start
period, thus excluding data from patients who discontinued
before the end of that period and resulting in potentially unbal-
anced treatment groups.
We recently proposed a new method for delayed-start an-
alyses developed to ameliorate some of the methodological
issues observed in previous applications of the delayed-start
design [6]. Applied to the delayed-start analyses of the
EXPEDITION program, this statistical method mitigates
the key analysis issues identified in the ADAGIO trial. In
particular, comparisons of treatment differences at the
beginning and end of the delayed-start period using a nonin-
feriority test eliminate the reliance on slopes, the propor-
tional noninferiority margin avoids the issues associated
with the absolute noninferiority margins, and a single
MMRM analysis model including all available data from
all randomized patients from the beginning of the placebo-
controlled period through the end of the delayed-start period
minimizes the potential for bias from unbalanced treatment
groups in the delayed-start period. Extensive simulation
studies have demonstrated that the methods used in our an-
alyses of the EXPEDITION program control type I error
(that is, controlling for false positives on the noninferiority
test for any given time point; P values at different time points
are not adjusted for multiplicity) and have good statistical
properties [6].
No widely accepted noninferiority margin exists in the
AD field. The rationale for a 50% noninferiority margin
has been described elsewhere [6]. Briefly, it was selected
because it represents a reasonable estimate of the largest
clinically acceptable loss of the treatment benefit, indicating
that no more than 50% of the treatment difference at the end
of the placebo-controlled period would be lost at the end of
the delayed-start period. In the event that a treatment had
both symptomatic and disease-modifying effects, use of a
50% noninferiority margin would ensure that if noninferior-
ity were met, at least half of the effect would be attributable
to a disease-modifying effect. Furthermore, a 50% noninfer-
iority margin has become standard in other therapeutic areas,
such as cardiovascular [13].
The 28-week duration of the delayed-start period for the
primary analysis time point was selected to balance the need
to allow delayed-start patients sufficient time to experience
potential symptomatic effects of solanezumab, but not so
long that discontinuations would lead to small numbers
and increased variability to the extent that results might be
difficult to interpret. As previously reported, the half-life
of solanezumab is approximately 28 days [14], thus
28 weeks, which is greater than five half-lives of solanezu-
mab, was chosen as adequate for delayed-start patients to
achieve pharmacokinetic equilibrium as well as likely to
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(the effects of most approved symptomatic AD treatments
peak in ,6 months) [6]. Although pharmacodynamic equi-
librium, as manifested by effects on clinical measures, could
lag pharmacokinetic equilibrium, the additional analysis of
time points after the 28 weeks allows assessment of that pos-
sibility. The current analyses including 2 years of the
delayed-start period provide an additional benefit in that
the delayed-start benefits of solanezumab may be examined
beyond the primary analysis time point.
Results for the ADAS-Cog14 and the ADCS-iADL at the
prespecified primary analysis time point of 108 weeks (that
is, 28 weeks in the delayed-start period) demonstrated that
starting solanezumab early had benefits that persisted after
placebo-treated patients began solanezumab 18 months later.
Although the MMSE showed a statistically significant differ-
ence between solanezumab and placebo at the end of the
placebo-controlled studies, the separationwas not statistically
significant and the noninferiority criterion was not met at
the 108-week time point. Generally, the results from the
ADAS-Cog14, ADCS-iADL, and MMSE showed consistent
benefits in the early-start group throughout the 3.5-year
EXPEDITION program, although not always meeting statis-
tical significance. Additionally, results from the by-study
analyses (that is, EXPEDITION through EXPEDITION-
EXT and EXPEDITION2 through EXPEDITION-EXT)
showed similar results. Results for the CDR-SB were more
difficult to interpret given the lack of statistical significance
in the placebo-controlled period, followed by noninferiority
and statistical significance at some points in the delayed-
start period; the CDR-SB did not show a possible drug effect
as clearly as the other scales measured. Safety analyses of the
delayed-start period support an acceptable safety profile of
solanezumab; no new safety signals were observed in the
delayed-start patients.
Although patients, investigators, and site personnel were
not blinded to treatments administered during the delayed-
start period (because all patients received solanezumab),
they were not informed of the individual treatment assigned
in the placebo-controlled period. In addition, no observable
effects of solanezumab, such as an AE or laboratory find-
ings, are known that would inadvertently break the blind.
Although the delayed-start period was an optional extension
to the double-blind study, the fact that the vast majority
(95%) of patients who finished the double-blind, both on
drug and on placebo, enrolled in the extension strengthens
the ability to compare treatment differences in the two
phases. Taken together, maintaining the blind for treatment
assignments during the placebo-controlled period and
the large numbers of patients who continued in
EXPEDITION-EXT create an opportunity to evaluate the
data in total in a manner similar to the delayed-start
design as originally proposed by Leber (1997) [2]. The
EXPEDITION3 study incorporates a delayed-start design
into a single protocol and will provide an opportunity to
confirm or refute these findings.Of the mild AD patients randomized in the EXPEDI-
TION program, 43% of delayed-start patients (n 5 286)
and 45% of early-start patients (n 5 295) completed the
entire 3.5-year analysis period. Although this amount of
attrition is not unexpected in a multiyear longitudinal study
of this patient population, it does have an impact, particu-
larly toward the later time points of the study, on power to
detect noninferiority and treatment differences. As shown
in Fig. 4 and Table 2, a pattern of increasing treatment differ-
ences in the placebo-controlled period, followed by more
stable differences during the delayed-start period was
observed for ADAS-Cog14, ADCS-iADL, and MMSE; how-
ever, increasing variability (as illustrated by increasing stan-
dard errors and widening confidence intervals) limited the
ability to establish noninferiority at later time points despite
largely similar differences between early-start and delayed-
start treatment groups. Simulation studies have previously
demonstrated the proposed statistical method is conserva-
tive, favoring control of type I error over power to detect
noninferiority based on the given sample size.With similarly
sized studies, approximately 50% power is estimated to
detect noninferiority at week 108 [6]. However, it is noted
that with approximately 600 patients in total completing
the 3.5-year study duration, this delayed-start program rep-
resents one of the largest clinical trial cohorts in AD patients
with long-term longitudinal data.
As noted previously, no new safety signals were identified
and the safety profile was consistent with previous safety
analyses of the EXPEDITIONprogram [7]. Small differences
in the frequency of individual AEs may be due to increased
patient age relative to the placebo-controlled period and to
longer exposure and observation time in this study.
Despite concerns about the analysis methods in ADA-
GIO, the delayed-start design remains as one possible option
to assess a drug’s effect on underlying disease progression.
At the end of the ADAGIO FDA Advisory Committee, com-
mittee members acknowledged its utility [12], and FDA
officials have reported elsewhere that results from an appro-
priately conducted delayed-start design could be interpreted
and used to demonstrate a disease-modifying effect [15,16].
In 2013, FDA issued draft guidance on developing drugs for
early stages of AD. The guidance states that an effect on a
biomarker in combination with clinical outcomes or an
alternative trial design, such as a delayed-start design, could
provide support for a disease-modifying effect of an investi-
gational drug [17].
The results of the delayed-start analyses of the
EXPEDITION studies suggest that for the ADAS-Cog14
and ADCS-iADL scales, the benefit observed at the end of
the placebo-controlled portion of the study persisted during
much of the delayed-start period, supporting initiation of
treatment as early as possible. While the AD field has not
arrived at a strong consensus on the definition of a clinically
meaningful effect of a disease-modifying treatment, the
1.8-point treatment difference on the ADAS-Cog14 observed
in pooled data from EXPEDITION and EXPEDITION2 at
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and the effect was sustained through 132 weeks, as evi-
denced by the delayed-start analysis. Furthermore, the treat-
ment effect in the placebo-controlled period is characterized
by an increasing pattern over time compared with placebo-
treated patients. The lack of statistically significant results
on the MMSE and CDR-SB scales warrants some caution
in drawing firm conclusions from these analyses. The safety
and efficacy of solanezumab treatment will continue to be
evaluated in the ongoing EXPEDITION3 study in patients
with mild AD (NCT01900665), providing an opportunity
to replicate these results.
These analyses further support the proposed method of
delayed-start analysis as an appropriate methodology for as-
certaining long-term effectiveness and possible disease-
modifying effects of AD treatments.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and
meeting abstracts and presentations regarding imple-
mentation of delayed-start analysis methods and in-
vestigations of other treatments for Alzheimer’s
disease (AD).
2. Interpretation: The results of the delayed-start ana-
lyses of the EXPEDITION studies suggest that for
the 14-item Alzheimer’s Disease Assessment Scale-
Cognitive subscale and Alzheimer’s Disease Coop-
erative Study Activities of Daily Living inventory,
instrumental item scales, the benefit observed at the
end of the placebo-controlled portion of the study
persisted during much of the delayed-start period.
3. Future directions: The safety and efficacy of solane-
zumab treatment will continue to be evaluated in the
ongoing EXPEDITION3 study in patients with mild
AD (NCT01900665); a delayed-start analysis has
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